## Paul Revill

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1740258/publications.pdf

Version: 2024-02-01

304743 214800 2,412 60 22 47 citations h-index g-index papers 62 62 62 3864 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. Value in Health, 2016, 19, 929-935.	0.3	589
2	The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. Value in Health, 2016, 19, 921-928.	0.3	203
3	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health, 2014, 2, e23-e34.	6.3	188
4	Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature, 2015, 528, S68-S76.	27.8	141
5	Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report. Value in Health, 2018, 21, 1133-1149.	0.3	94
6	Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa. Journal of Infectious Diseases, 2017, 215, 1362-1365.	4.0	90
7	Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. Lancet HIV,the, 2019, 6, e116-e127.	4.7	84
8	Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. Lancet HIV,the, 2018, 5, e146-e154.	4.7	61
9	The impact and costâ€effectiveness of communityâ€based <scp>HIV</scp> selfâ€testing in subâ€Saharan Africa: a health economic and modelling analysis. Journal of the International AIDS Society, 2019, 22, e25243.	3.0	60
10	Potential effect of household contact management on childhood tuberculosis: a mathematical modelling study. The Lancet Global Health, 2018, 6, e1329-e1338.	6.3	59
11	Assessment of the Potential Impact and Cost-effectiveness of Self-Testing for HIV in Low-Income Countries. Journal of Infectious Diseases, 2015, 212, 570-577.	4.0	57
12	Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. The Lancet Global Health, 2014, 2, e35-e43.	6.3	44
13	Supporting the development of a health benefits package in Malawi. BMJ Global Health, 2018, 3, e000607.	4.7	42
14	Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. Lancet HIV,the, 2020, 7, e193-e200.	4.7	41
15	Modeling the epidemiological impact of the UNAIDS 2025 targets to end AIDS as a public health threat by 2030. PLoS Medicine, 2021, 18, e1003831.	8.4	41
16	Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis. Lancet HIV,the, 2014, 1, e85-e93.	4.7	39
17	Early infant diagnosis of HIV infection in low-income and middle-income countries: does one size fit all?. Lancet Infectious Diseases, The, 2014, 14, 650-655.	9.1	38
18	Strategies for Efficient Computation of the Expected Value of Partial Perfect Information. Medical Decision Making, 2014, 34, 327-342.	2.4	32

#	Article	IF	Citations
19	The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis. The Lancet Global Health, 2021, 9, e620-e627.	6.3	31
20	Costâ€effectiveness of routine viral load monitoring in low―and middle―ncome countries: a systematic review. Journal of the International AIDS Society, 2017, 20, e25006.	3.0	27
21	Using modeling to inform international guidelines for antiretroviral treatment. Aids, 2014, 28, S1-S4.	2.2	24
22	Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income Settings. PLoS ONE, 2014, 9, e109148.	2.5	24
23	Methods to promote equity in health resource allocation in low- and middle-income countries: an overview. Globalization and Health, 2020, 16, 6.	4.9	23
24	Point-of-Care Viral Load Testing for Sub-Saharan Africa: Informing a Target Product Profile. Open Forum Infectious Diseases, 2016, 3, ofw161.	0.9	22
25	Potential Impact and Cost-Effectiveness of Condomless-Sex–Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance. Journal of Infectious Diseases, 2021, 223, 1345-1355.	4.0	22
26	The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study. Lancet Public Health, The, 2019, 4, e127-e136.	10.0	21
27	Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa. PLoS ONE, 2016, 11, e0167654.	2.5	20
28	Costâ€perâ€diagnosis as a metric for monitoring costâ€effectiveness of HIV testing programmes in lowâ€income settings in southern Africa: health economic and modelling analysis. Journal of the International AIDS Society, 2019, 22, e25325.	3.0	20
29	Factors influencing job preferences of health workers providing obstetric care: results from discrete choice experiments in Malawi, Mozambique and Tanzania. Globalization and Health, 2016, 12, 86.	4.9	19
30	Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. Lancet HIV,the, 2022, 9, e353-e362.	4.7	19
31	Improving survival of retinoblastoma in Uganda. British Journal of Ophthalmology, 2015, 99, 937-942.	3.9	18
32	Overcoming roadblocks in the development of vaccines for leishmaniasis. Expert Review of Vaccines, 2021, 20, 1419-1430.	4.4	18
33	Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care. PLoS ONE, 2018, 13, e0190283.	2.5	16
34	Developing the EQ-5D-5L Value Set for Uganda Using the â€~Lite' Protocol. Pharmacoeconomics, 2022, 40, 309-321.	3.3	14
35	Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates. PLoS Neglected Tropical Diseases, 2022, 16, e0010471.	3.0	14
36	Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa. Journal of Infectious Diseases, 2016, 214, 73-79.	4.0	13

#	Article	IF	CITATIONS
37	The Methodological Challenges for the Estimation of Quality of Life in Children for Use in Economic Evaluation in Low-Income Countries. Value in Health Regional Issues, 2013, 2, 231-239.	1.2	11
38	Factors associated with healthcare seeking behaviour for children in Malawi: 2016. Tropical Medicine and International Health, 2020, 25, 1486-1495.	2.3	11
39	Causal effects of HIV on employment status in low-income settings. Economics and Human Biology, 2017, 27, 248-260.	1.7	10
40	Fresh Money for Health? The (False?) Promise of "Innovative Financing―for Health in Malawi. Health Systems and Reform, 2018, 4, 324-335.	1.2	10
41	Shifting human resources for health in the context of ART provision: qualitative and quantitative findings from the Lablite baseline study. BMC Health Services Research, 2016, 16, 660.	2.2	9
42	A one stop shop for cost-effectiveness evidence? Recommendations for improving Disease Control Priorities. Cost Effectiveness and Resource Allocation, 2019, 17, 7.	1.5	9
43	Examining the use of economic evaluations in health-related humanitarian programmes in low- and middle-income countries: a systematic review. Health Policy and Planning, 2020, 35, 210-218.	2.7	9
44	Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys. International Health, 2017, 9, 91-99.	2.0	8
45	Program Evaluation of Population- and System-Level Policies: Evidence for Decision Making. Medical Decision Making, 2022, 42, 17-27.	2.4	8
46	Potential impact of intervention strategies on COVID-19 transmission in Malawi: a mathematical modelling study. BMJ Open, 2021, 11, e045196.	1.9	8
47	Appraising the value of evidence generation activities: an HIV modelling study. BMJ Global Health, 2018, 3, e000488.	4.7	7
48	Patient-level benefits associated with decentralization of antiretroviral therapy services to primary health facilities in Malawi and Uganda. International Health, 2018, 10, 8-19.	2.0	6
49	Allocating resources to support universal health coverage: development of a geographical funding formula in Malawi. BMJ Global Health, 2020, 5, e002763.	4.7	6
50	Optimizing infant HIV diagnosis with additional screening at immunization clinics in three subâ€Saharan African settings: a costâ€effectiveness analysis. Journal of the International AIDS Society, 2021, 24, e25651.	3.0	5
51	Using Economic Evaluation to Inform Responses to the Opioid Epidemic in the United States: Challenges and Suggestions for Future Research. Substance Use and Misuse, 2022, 57, 815-821.	1.4	5
52	Socio-demographic factors associated with early antenatal care visits among pregnant women in Malawi: 2004–2016. PLoS ONE, 2022, 17, e0263650.	2.5	4
53	Estimating the health burden of road traffic injuries in Malawi using an individual-based model. Injury Epidemiology, 2022, 9, .	1.8	4
54	Practical metrics for establishing the health benefits of research to support research prioritisation. BMJ Global Health, 2020, 5, e002152.	4.7	3

#	Article	IF	CITATION
55	Perspectives on the use of modelling and economic analysis to guide HIV programmes in sub-Saharan Africa. Lancet HIV,the, 2022, 9, e517-e520.	4.7	3
56	Measuring and Valuing Informal Care for Economic Evaluation of HIV/AIDS Interventions: Methods and Application in Malawi. Value in Health Regional Issues, 2016, 10, 73-78.	1.2	2
57	Pre-exposure prophylaxis is cost-effective for HIV in the UK. Lancet Infectious Diseases, The, 2018, 18, 10-11.	9.1	2
58	Differentiated prevention and care to reduce the risk of HIV acquisition and transmission among female sex workers in Zimbabwe: study protocol for the â€~AMETHIST' cluster randomised trial. Trials, 2022, 23, 209.	1.6	2
59	Concomitant health benefits package design and research prioritisation: development of a new approach and an application to Malawi. BMJ Global Health, 2021, 6, e007047.	4.7	1
60	The costâ€effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa. Journal of the International AIDS Society, 2020, 23, e25469.	3.0	0